Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Home » Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

GH AMEA on Social Media Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
GH AMEA

Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and can guide appropriate treatment selection. https://lnkd.in/guTdfVf

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial - Guardant Health AMEA

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Home » Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

GH AMEA on Social Media Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
GH AMEA

Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and can guide appropriate treatment selection. https://lnkd.in/guTdfVf

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us